人人看懂PD-1：小细胞肺癌一线数据

一图读懂中国PD-1/PD-L1 | 2021.12.12人人看懂PD-1：非小细胞肺癌非鳞一线数据（12.18）人人看懂PD-1：非小细胞肺肺鳞癌一线数据（12.23）参考文献（上下滑动查看更多）[1]Jonathan W Goldman, Mikhail Dvorkin, Yuanbin Chen, et al. Durvalumab,with or without tremelimumab,plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer(CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial.The Lancet Oncology.2020.[2]Overall survival with first-line durvalumab plus platinum-etoposide in patients with extensive-stage (ES)-SCLC in CASPIAN: Subgroup findings from Asia.2019 ESMO ASIA.[3]Jonathan W G , Marina C G, Yuanbin Chen,et al. Patient-reported outcomes with first-line durvalumab plus platinum-etoposide versus platinum-etoposide in extensive-stage s ………………………………